In the latest trading session,, 0.39 million Rallybio Corp (NASDAQ:RLYB) shares changed hands as the company’s beta touched -1.13. With the company’s most recent per share price at $0.5 changing hands around $0.01 or 2.44% at last look, the market valuation stands at $20.82M. RLYB’s current price is a discount, trading about -208.0% off its 52-week high of $1.54. The share price had its 52-week low at $0.22, which suggests the last value was 56.0% up since then. When we look at Rallybio Corp’s average trading volume, we note the 10-day average is 1.32 million shares, with the 3-month average coming to 2.81 million.
Analysts gave the Rallybio Corp (RLYB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RLYB as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Rallybio Corp’s EPS for the current quarter is expected to be -0.25.
Rallybio Corp (NASDAQ:RLYB) trade information
Instantly RLYB is in green as seen in intraday trades today. With action 15.73%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -62.67%, with the 5-day performance at 15.73% in the green. However, in the 30-day time frame, Rallybio Corp (NASDAQ:RLYB) is 60.37% up. Looking at the short shares, we see there were 0.35 million shares sold at short interest cover period of 1.11 days.
Rallybio Corp (RLYB) estimates and forecasts
Year-over-year growth is forecast to reach -68.55% down from the last financial year.
The company’s revenue for the corresponding quarters a year ago was 299k and 299k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -100.00%. The estimates for the next quarter sales put growth at -100.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -19.41%. The 2025 estimates are for Rallybio Corp earnings to increase by 24.06%.
RLYB Dividends
Rallybio Corp is expected to release its next quarterly earnings report on 2025-May-08.
Rallybio Corp (NASDAQ:RLYB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.16% of Rallybio Corp shares while 75.48% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 78.75%. There are 75.48% institutions holding the Rallybio Corp stock share, with VIKING GLOBAL INVESTORS LP the top institutional holder. As of 2024-06-30, the company held 10.288% of the shares, roughly 4.19 million RLYB shares worth $5.62 million.
JOHNSON & JOHNSON holds the second largest percentage of outstanding shares, with 8.9184% or 3.64 million shares worth $4.87 million as of 2024-06-30.
